Subarachnoid hemorrhage, following rupture of an intracranial aneurysm, affects about 25 000 people in the U.S. each year. Less than half the patients who survive until hospital admission have an overall favorable outcome. This high morbidity and mortality rate is a result of serious complications following the initial subarachnoid hemorrhage, the most significant of these being rebleeding and cerebral ischemia secondary to vasospasm. While surgical clipping of the aneurysm is the most definitive therapy, this procedure may be postponed for a week or two after the initial hemorrhage, depending on the patient's clinical condition. Pharmacological therapy is a critical part of the preoperative care of these patients and of the postoperative management of complications. This article discusses the syndromes of rebleeding and vasospasm and reviews the current pharmacologic therapy for each.
AdamsHP. Current status of antifibrinolytic therapy for treatment of patients with aneurysmal subarachnoid hemorrhage. Stroke1982; 13: 256–9.
4.
SundtTMWhisnantJP. Subarachnoid hemorrhage from intracranial aneurysm. N Engl J Med1978; 299: 116–22.
5.
AdamsHPJergensonDDKassellNFSahsAL. Pitfalls in the recognition of subarachnoid hemorrhage. JAMA1980; 244: 794–6.
6.
Neil-DwyerGCruickshankJDoshiAWalterP.Systemic effects of subarachnoid hemorrhage. In: WilkinsRH, ed. Cerebral arterial spasm: Proceedings of the Second International Workshop. Baltimore: Williams and Wilkins, 1980: 256–65.
7.
DoshiRNeil-DwyerG.A clinicopathological study of patients following a subarachnoid hemorrhage. J Neurosurg1980; 52: 295–301.
8.
AdamsHPNibbelinkDWTomerJCSahsAL. Antifibrinolytic therapy in patients with aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. Arch Neurol1981; 38: 25–9.
LocksleyHB. Natural history of subarachnoid hemorrhage, intracranial hemorrhage, aneurysms and arteriovenous malformations. Based on 6368 cases in the Cooperative Study. J Neurosurg1966; 25: 321–68.
11.
JaneJAWinnHRRichardsonAE. The natural history of intracranial aneurysms: Rebleeding rates during the acute and long term period and implication for surgical management. Clin Neurosurg1977; 24: 176–84.
SundtTM. Cerebral vasospasm following subarachnoid hemorrhage: Evolution, management and relationship to timing of surgery. Clin Neurosurg1977; 24: 228–39.
14.
ArutiunovAIBaronMAMajorovaNA. Experimental and clinical study of the development of spasm of the cerebral arteries related to subarachnoid hemorrhage. J Neurosurg1970; 32: 617–25.
15.
SundtTM. Blood flow regulation in normal and ischemic brain. Kalamazoo: The Upjohn Co., 1979: 24–5.
KasteMRamseyM.Tranexamic acid in subarachnoid hemorrhage. A double-blind study. Stroke1979; 10: 519–22.
21.
SenguptaRPSoSCVillarejo-OrtegaFJ. Use of epsilon aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysm. J Neurosurg1976; 44: 479–84.
22.
ChowdharyVMCareyPCHusseinMM. Prevention of early recurrence of spontaneous subarachnoid hemorrhage by epsilon aminocaproic acid. Lancet1979; 2: 741–3.
23.
ChadraB.Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysms with tranexamic acid. A double-blind clinical trial. Ann Neurol1978; 3: 502–4.
24.
AlkjaersigNFletcherAPSherryS.Epsilon aminocaproic acid, an inhibitor of plasminogen activation. J Biol Chem1959; 234: 832–7.
25.
AmbrusCMAmbrusJLLassmanHBMinkIB. Studies on the mechanism of action of inhibitors of the fibrinolytic system. Ann NY Acad Sci1968; 146: 430–47.
26.
NibbelinkDWJacobsonCD. Plasminogen depletion during administration of epsilon-aminocaproic acid. Thrombos Diathes Haemorrh1973; 29: 598–602.
27.
McNicolGPFletcherAPAlkjaersigNSherryS.The absorption, distribution, and excretion of epsilon-aminocaproic acid following oral or intravenous administration to man. J Lab Clin Med1962; 59: 15–24.
28.
NibbelinkDWTornerJCHendersonWG. Intracranial aneurysms and subarachnoid haemorrhage. A cooperative study. Antifibrinolytic therapy in recent onset subarachnoid hemorrhage. Stroke1975; 6: 622–9.
29.
GeronemusRHerzDAShulmanK.Streptokinase clot lysis time in patients with ruptured intracranial aneurysms. J Neurosurg1974; 40: 499–503.
30.
Maurice-WilliamsRS. Prolonged antifibrinolysis: An effective non-surgical treatment of ruptured intracranial aneurysm?. Br Med J1978; 1: 945–7.
31.
SchisanoG.The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage. Surg Neurol1978; 10: 517–22.
32.
MakiMBellerFK. Comparative studies of fibrinolytic inhibitors in vitro. Thrombos Diathes Haemorrh1966; 16: 668–86.
33.
WaltonJN. Subarachnoid haemorrhage. Edinburgh: E & S Livingstone, 1956: 48–64.
34.
NilssonIMAndersonLBjorkmanSE. Epsilon-aminocaproic acid (EACA) as a therapeutic agent based on five years clinical experience. Acta Med Scand1966; (suppl 448): 1–46.
35.
SundtTMOnofrioBMMeridethJ.Treatment of cerebral vasospasm from subarachnoid hemorrhage with isoproterenol and lidocaine hydrochloride. J Neurosurg1973; 38: 664–6.
36.
FlammES. Treatment of cerebral vasospasm with aminophylline and isoproterenol. In: WilkinsRH, ed. Cerebral arterial spasm: Proceedings of the Second International Workshop. Baltimore: Williams and Wilkins, 1980: 575–7.
37.
SundtTM. The role of isoproterenol in the treatment of vasospasm. In: WilkinsRH, ed. Cerebral arterial spasm: Proceedings of the Second International Workshop. Baltimore: Williams and Wilkins, 1980: 572–4.
38.
FlammESViauATRansohoffJNaftchiNE. Experimental alterations in cyclic adenosine monophosphate concentrations in the cat basilar artery. Neurology1976; 26: 664–6.
39.
FleischerASRaggioJFTindallGG. Aminophylline and isoproterenol in the treatment of cerebral vasospasm. Surg Neurol1977; 8: 117–21.
40.
WeinbergerMWMatthayRAGinchanskyEJ, Intravenous aminophylline dosage. Use of serum theophylline measurement for guidance. JAMA1976; 235: 2110–3.
41.
FerrisEJAthanasoulisCAShapiroJHDuffieldR.Pharmacological aspects of intracranial spasm secondary to cerebral hemorrhage: Experimental observations. Radiology1970; 95: 561–6.
42.
GiannottaSLKindtGWHaarFL. Topical lidocaine in treatment of cerebral vasospasm. Surg Neurol1975; 4: 13–16.
43.
WilkinsRH. Attempts at treatment of intracranial arterial spasm in animals and human beings. Surg Neurol1973; 1: 148–59.
44.
ZervasNTCandiaMCandiaG, Reduced incidence of cerebral ischemia following rupture of intracranial aneurysms. Surg Neurol1979; 11: 339–44.
45.
MarkwardtF.Influence of drugs and enzymes on platelet 5-hydroxytryptamine. Ann Med Exp Biol Fenn1968; 46: 407–15.
46.
ZervasNTKuwayamaARosoffCBSalzmanEW. Cerebral arterial spasm. Modification by inhibition of platelet function. Arch Neurol1973; 28: 400–4.
47.
MuschollEVogtM.The action of reserpine on the peripheral sympathetic system. J Physiol1958; 141: 132–55.
48.
RosoffCBSalzmanEWGurewichV.Reduction of platelet serotonin and the responses to pulmonary emboli. Surgery1971; 70: 12–19.
49.
ZervasNTHoriHRosoffCB. Experimental inhibition of serotonin by antibiotics: Prevention of cerebral vasospasm. J Neurosurg1974; 41: 59–62.
50.
ZervasNTKistlerJPPloetzJP. Effect of reserpine and kanamycin on postoperative delayed ischemic deficits in patients with subarachnoid hemorrhage after aneurysm rupture. In: WilkinsRH, ed. Cerebral arterial spasm: Proceedings of the Second International Workshop. Baltimore: Williams and Wilkins, 1980: 514–7.
51.
BlumenkopfBWilkinsRHFeldmanJM. Cerebral vasospasm and delayed neurological deficit after aneurysm rupture despite administration of reserpine and kanamycin. In: WilkinsRH, ed. Cerebral arterial spasm: Proceedings of the Second International Workshop. Baltimore: Williams and Wilkins, 1980: 518–24.
52.
TinkerJHMichenfelderJD. Sodium nitroprusside. Pharmacology, toxicology and therapeutics. Anesthesiology1976; 45: 340–54.
53.
AllanGS. Cerebral arterial spasm. Part 8. The treatment of delayed cerebral arterial spasm in human beings. Surg Neurol1976; 6: 71–80.
54.
CottrellJEPatelKTurndorfHRansohoffJ.Intracranial pressure changes induced by sodium nitroprusside with intracranial mass lesions. J Neurosurg1978; 48: 329–31.
OgataMMarshallBMLougheedWM. Observation on the effects of intrathecal papaverine in experimental vasospasm. J Neurosurg1973; 38: 20–5.
57.
OlesenJPaulsonOB. The effect of intra-arterial papaverine on the regional cerebral blood flow in patients with stroke or intracranial tumor. Stroke1971; 2: 148–59.
58.
MohanJ.The neurosurgeon's view. In: BoullinDJ, ed. Cerebral vasospasm. New York: John Wiley, 1980: 15–35.
59.
GiannottaSLMcGillicuddyJEKindtGW. Diagnosis and treatment of postoperative cerebral vasospasm. Surg Neurol1977; 8: 286–9.
60.
KosnikEJHuntWE. Postoperative hypertension in the management of patients with intracranial arterial aneurysms. J Neurosurg1976; 45: 148–54.
61.
PutzMBGiannottaSLKindtGW, Treatment of patients with neurological deficits associated with cerebral vasospasm by intravascular volume expansion. Neurosurgery1978; 3: 364–8.
62.
BurkeAMChienSMcMurtryJG. Effects of low molecular weight dextran on blood viscosity after craniotomy for intracranial aneurysm. Surg Gynecol Obstet1979; 148: 9–15.
63.
BoschensteinFKReillyJAYahrMDCorrellJW. Effect of low molecular weight dextran on cortical blood flow. Arch Neurol1966; 14: 288–93.
64.
SamsonDSBeyerCM. Thiopental coma in the treatment of vasospasm-induced cerebral ischemia/infarction. In: WilkinsRH, ed. Cerebral arterial spasm: Proceedings of the Second International Workshop. Baltimore: Williams and Wilkins1980: 634–6.
KassellNFPeerlessSJDrakeCGAdamsHP. High dose barbiturate therapy of cerebral vasospasm: Preliminary results. In: WilkinsRH, ed. Cerebral arterial spasm: Proceedings of the Second International Workshop. Baltimore: Williams and Wilkins, 1980: 628–32.
69.
DiazFGQuandtCMde los ReyesRA, The use of an ultrashort acting barbiturate in the treatment of intracranial hypertension. Scientific manuscripts. American Association of Neurological Surgeons Annual Meeting. 1980: 174–5.
70.
KassellNFPeerlessSJDrakeCGAdamsHP. Treatment of ischemic deficits from cerebral vasospasm with high dose barbiturate therapy. Neurosurgery1980; 7: 593–7.
71.
RockoffMAMarshallLFShapiroHM. High dose barbiturate therapy in humans: A clinical review of 60 patients. Ann Neurol1978; 6: 194–9.
72.
QuandtCMde los ReyesRADiazFG. Barbiturate-induced coma for the treatment of cerebral ischemia: Review of outcome. Clin Pharm1982; in press.
73.
CohenRJAllenGS. Cerebral arterial spasm: The role of calcium in in vitro analysis of treatment with nifedipine and Nimodipine. In: WilkinsRH, ed. Cerebral arterial spasm: Proceedings of the Second International Workshop. Baltimore: Williams and Wilkins, 1980: 527–32.
74.
ShimizaKOhtaTTodaN.Evidence for greater susceptibility of isolated dog cerebral arteries to Ca antagonists than peripheral arteries. Stroke1980; 11: 261–6.
75.
BrandtLAnderssonKEBengtssonBEdvinssonLLjunggrenBMackenzieET. Effects of a calcium antagonist on cerebrovascular smooth muscle in vitro and in vivo. In: WilkinsRH, ed. Cerebral arterial spasm: Proceedings of the Second International Workshop. Baltimore: Williams and Wilkins, 1980: 604–7.
76.
BoullinDJ. Potential use of prostacyclin in the treatment of vasospasm. In: WilkinsRH, ed. Cerebral arterial spasm: Proceedings of the Second International Workshop. Baltimore: Williams and Wilkins, 1980: 533–9.
77.
BoullinDJBuntingSBlasoWPHuntTMMoncadaS.Responses of human and baboon arteries to prostaglandin endoperoxides and biologically generated and synthetic prostacyclin: Their relevance to cerebral arterial spasm in man. Br J Clin Pharmacol1979; 7: 139–47.
78.
RosenblumWIEl-SabbanF.Dimethyl sulfoxide (DMSO) and glycerol, hydroxyl radical scavengers, impair platelet aggregation within and eliminate the accompanying vasodilation of injured mouse pial arterioles. Stroke1982; 13: 35–9.
79.
MullenSJafarJHanlonKBrownF.Dimethyl sulfoxide in the management of postoperative hemiplegia. In: WilkinsRH, ed. Cerebral arterial spasm: Proceedings of the Second International Workshop. Baltimore: Williams and Wilkins, 1980: 646–53.
